{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:32:50Z","timestamp":1788255170648,"version":"build-2803163510"},"reference-count":18,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomised patients (N\u2009=\u2009900) received monthly subcutaneous injections of placebo, erenumab 70 mg, or 140 mg (3:3:2) for 3 months. Primary endpoint was change from baseline in monthly migraine days at Month 3. Other endpoints included achievement of \u226550%, \u226575%, and 100% reduction in monthly migraine days, change in monthly acute migraine-specific medication treatment days, patient-reported outcomes, and safety assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, mean (standard deviation) age was 37.5 (9.9) years, 81.9% were women, and monthly migraine days was 8.2 (2.8). At Month 3, change from baseline in monthly migraine days (primary endpoint) was \u22123.1, \u22124.2, and \u22124.8 days for placebo, erenumab 70 mg, and erenumab 140 mg, respectively, with a statistically significant difference for erenumab versus placebo (P\u2009=\u20090.002 [70 mg], P\u2009&lt;\u20090.001 [140 mg]). Both erenumab doses were also significantly superior to placebo on all secondary endpoints, including the proportion of patients achieving \u226550% reduction from baseline in monthly migraine days, change from baseline in monthly acute migraine-specific medication treatment days and change from baseline in the Headache Impact Test-6\u2122 scores. The safety profile of erenumab was comparable with placebo; no new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study of erenumab in patients with episodic migraine from Asia, the Middle East, and Latin America met all primary and secondary endpoints. A consistent numerical benefit was observed with erenumab 140 mg versus erenumab 70 mg across all efficacy endpoints. These findings extend evidence of erenumab\u2019s efficacy and safety to patients under-represented in previous trials. ClinicalTrials.gov identifier: NCT03333109<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211024160","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T02:32:11Z","timestamp":1624674731000},"page":"1285-1297","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":63,"title":["Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5358","authenticated-orcid":false,"given":"Shuu-Jiun","family":"Wang","sequence":"first","affiliation":[{"name":"Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Brain Research Center and College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Artemio A","family":"Roxas","sequence":"additional","affiliation":[{"name":"The Medical City, Pasig, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"Saravia","sequence":"additional","affiliation":[{"name":"Mautalen Salud e Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Neurology, G B Pant Institute of Post Graduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-9698","authenticated-orcid":false,"given":"Naji","family":"Riachi","sequence":"additional","affiliation":[{"name":"Lebanese American University Medical Center Rizk Hospital, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling Sharon","family":"Tai","sequence":"additional","affiliation":[{"name":"University of Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surat","family":"Tanprawate","sequence":"additional","affiliation":[{"name":"Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Tran","family":"Ngoc","sequence":"additional","affiliation":[{"name":"University Medical Center, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Neuroscience Institute \u2013 Singapore General Hospital Campus, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaloo","family":"Pandhi","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7267-8505","authenticated-orcid":false,"given":"Subhayan","family":"Mondal","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Tenenbaum","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Hours-Zesiger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"bibr1-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.071"},{"key":"bibr2-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"bibr3-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"bibr4-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"bibr5-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1111\/head.13275"},{"key":"bibr6-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412468668"},{"key":"bibr7-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1111\/head.12328"},{"key":"bibr8-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"bibr9-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"bibr10-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"bibr11-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"bibr12-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr13-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652"},{"key":"bibr14-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"bibr15-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419854082"},{"key":"bibr16-03331024211024160","unstructured":"European Medicines Agency. EMEA\/H\/C\/004447 \u2013 PSUSA\/00010699\/201911. AIMOVIG Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf (Revised Sep 2020, accessed 11 March 2021)."},{"key":"bibr17-03331024211024160","unstructured":"Food and Drug Administration. AIMOVIG (erenumab-aooe). Highlights of Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761077s007lbl.pdf (Revised Apr 2020, accessed 11 March 2021)."},{"key":"bibr18-03331024211024160","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420912726"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211024160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211024160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211024160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:08Z","timestamp":1777387748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211024160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1177\/03331024211024160"],"URL":"https:\/\/doi.org\/10.1177\/03331024211024160","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}